- Home
- OOMA vs MREO Comparison
OOMA vs MREO Comparison
Compare OOMA & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OOMA
- MREO
- Stock Information
- Founded
- OOMA 2003
- MREO 2015
- Country
- OOMA United States
- MREO United Kingdom
- Employees
- OOMA N/A
- MREO N/A
- Industry
- OOMA EDP Services
- MREO Biotechnology: Pharmaceutical Preparations
- Sector
- OOMA Technology
- MREO Health Care
- Exchange
- OOMA Nasdaq
- MREO Nasdaq
- Market Cap
- OOMA 345.3M
- MREO 281.6M
- IPO Year
- OOMA 2015
- MREO N/A
- Fundamental
- Price
- OOMA $13.09
- MREO $1.77
- Analyst Decision
- OOMA Strong Buy
- MREO Strong Buy
- Analyst Count
- OOMA 5
- MREO 5
- Target Price
- OOMA $17.63
- MREO $7.40
- AVG Volume (30 Days)
- OOMA 215.3K
- MREO 899.2K
- Earning Date
- OOMA 08-26-2025
- MREO 11-11-2025
- Dividend Yield
- OOMA N/A
- MREO N/A
- EPS Growth
- OOMA N/A
- MREO N/A
- EPS
- OOMA N/A
- MREO N/A
- Revenue
- OOMA $261,617,000.00
- MREO $500,000.00
- Revenue This Year
- OOMA $6.45
- MREO N/A
- Revenue Next Year
- OOMA $5.70
- MREO $55.50
- P/E Ratio
- OOMA N/A
- MREO N/A
- Revenue Growth
- OOMA 5.42
- MREO N/A
- 52 Week Low
- OOMA $10.88
- MREO $1.47
- 52 Week High
- OOMA $17.00
- MREO $4.72
- Technical
- Relative Strength Index (RSI)
- OOMA 60.70
- MREO 49.96
- Support Level
- OOMA $12.43
- MREO $1.71
- Resistance Level
- OOMA $13.28
- MREO $1.80
- Average True Range (ATR)
- OOMA 0.36
- MREO 0.08
- MACD
- OOMA 0.01
- MREO 0.01
- Stochastic Oscillator
- OOMA 77.70
- MREO 50.00
About OOMA Ooma Inc.
Ooma Inc is a communications services company. It is a smart software-as-a-service (SaaS) and unified communications platform that deliver voice and collaboration features including messaging, intelligent virtual attendants and video conferencing, and residential phone service provides PureVoice high-definition voice quality, advanced functionality and integration with mobile devices. Its services rely upon the following main elements: multi-tenant cloud service, on-premise devices, desktop and mobile applications, and calling platforms. It generates revenues from the sale of subscriptions and other services.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).